Ridge Properties DBA Pain Relief Naturally Issues Voluntary Nationwide Recall of all lots of Naturally HL Bedsore Cream, Pretat by TAT Balm Carbomer Free Gel, & All Naturally HL Hemorrhoid products due to manufacturing concerns at the facility
Ridge Properties DBA Pain Relief Naturally is voluntarily recalling all lots within expiry of Naturally HL Bedsore Relief Cream, Extra Strength PreTAT by TAT Balm Carbomer Free Gel and Extra Strength Naturally HL Hemorrhoid Numbing with Lidocaine manufactured by Ridge Properties dba Pain Relief Naturally, Salem, Oregon to the consumer level. These products are being recalled after an FDA inspection found significant violations of current good manufacturing practice regulations. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 3, 2017 Category: Food Science Source Type: news
Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - November 2, 2017 Category: Drugs & Pharmacology Source Type: news
Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - October 25, 2017 Category: Drugs & Pharmacology Source Type: news
Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Updated - Currently in Shortage
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - October 23, 2017 Category: Drugs & Pharmacology Source Type: news
Inserting a cannula into a vein
(Deutsches Aerzteblatt International) Patients who are given a local anesthetic before having a venous cannula inserted have a clearly reduced sensation of pain when larger gauge cannulas are used. Compared with intradermal lidocaine infusion, the use of vapocoolant spray has the advantage that the rate of venepuncture failures is lower. This is the conclusion reached by Dirk R ü sch and coauthors from Marburg University based on a randomized controlled trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 13, 2017 Category: International Medicine & Public Health Source Type: news
Auburn therapeutic company receives FDA drug approval
Vitruvias Therapeutics LLC, an Auburn-based drug company, has received approval of a new drug application from the U.S. Food and Drug Administration for a new drug.
Vitruvias developed the drug with Sunny Pharmtech, a Taiwan-based API and drug development company. Sunny Pharmtech leaders said the jointly filed application received approval quickly.
The drug, lidocaine ointment USP 5 percent, is the first generic approval for both companies and is also part o f a joint development agreement that… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 29, 2017 Category: Biotechnology Authors: Tyler Patchen Source Type: news
Auburn therapeutic company receives FDA drug approval
Vitruvias Therapeutics LLC, an Auburn-based drug company, has received approval of a new drug application from the U.S. Food and Drug Administration for a new drug.
Vitruvias developed the drug with Sunny Pharmtech, a Taiwan-based API and drug development company. Sunny Pharmtech leaders said the jointly filed application received approval quickly.
The drug, lidocaine ointment USP 5 percent, is the first generic approval for both companies and is also part o f a joint development agreement that… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 29, 2017 Category: Health Management Authors: Tyler Patchen Source Type: news
Your NEJM Group Today: Eradicating TB in U.S. / Lidocaine for IUD Insertion / Pennsylvania Internist Opportunities (FREE)
By the Editors
Here ' s what we chose for you from NEJM Group today:NEJM Audio … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 21, 2017 Category: Primary Care Source Type: news
Lidocaine Nerve Block Reduces the Pain of IUD Insertion in Young Women Lidocaine Nerve Block Reduces the Pain of IUD Insertion in Young Women
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
SAN DIEGO, Aug. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of Sorrento, resubm... Biopharmaceuticals, Drug Delivery, FDA Sorrento Therapeutics, SCILEX Pharmaceuticals, ZTlido, lidocaine patch (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 29, 2017 Category: Pharmaceuticals Source Type: news
Sorrento seeks FDA nod for lidocaine patch
Sorrento Therapeutics (NSDQ:SRNE) said today that its subsidiary Scilex Pharmaceuticals resubmitted the new drug application for its lidocaine patch, ZTlido, to the FDA.
The San Diego, Calif.-based company is developing the drug-device product for the relief of pain associated with post-herpetic neuralgia.
Get the full story at our sister site, Drug Delivery Business News.
The post Sorrento seeks FDA nod for lidocaine patch appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 29, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat Scilex Pharmaceuticals Sorrento Therapeutics Source Type: news
Sorrento Therapeutics, Inc. Submits NDA For ZTlido Next-Generation Lidocaine Patch
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ( " Sorrento " ), announced today that SCILEX Pharmaceuticals Inc. ( " SCILEX " ), a majority-owned subsidiary of Sorrento, resubmitted the NDA and responded to all of FDA... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 29, 2017 Category: Drugs & Pharmacology Source Type: news
Lignospan Standard (Lidocaine HCl 2% and Epinephrine Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 10, 2017 Category: Drugs & Pharmacology Source Type: news
Lignospan Standard (Lidocaine HCl 2% and Epinephrine Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 9, 2017 Category: Drugs & Pharmacology Source Type: news
Lignospan Forte (Lidocaine HCl 2% and Epinephrine for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 9, 2017 Category: Drugs & Pharmacology Source Type: news
